Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Arbor, a US Gene Editing Company, Raises $215 Million Led by Singapore, Hong Kong, US Investors

publication date: Nov 9, 2021

Arbor Biotech, a Cambridge MA gene editing company, raised $215 million in an oversubscribed B round led by Temasek (the sovereign wealth fund of Singapore), Ally Bridge (headquartered in Hong Kong) and TCG Crossover of the US. Arbor was founded in 2016 by star CRISPR-Cas9 researcher Feng Zhang, among others. Dr. Zhang has positions at MIT and the Broad Institute. Arbor has worked to develop additional gene editing technologies to CRISPER-Cas9, but now is pivoting towards developing therapies, with an initial aim at liver and CNS targets. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital